GXMGal effect on different subsets of Treg cells. by Eva Pericolini (290617)

GXMGal effect on Th17 response. by Eva Pericolini (290617)

GXMGal effect on Treg cell response. by Eva Pericolini (290617)

Video2_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Video1_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Video6_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.MOV by Wesam S. Ahmed (10170053)

Video3_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Video4_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Video8_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.MOV by Wesam S. Ahmed (10170053)

Video2_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Video7_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.MOV by Wesam S. Ahmed (10170053)

Video1_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Video3_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Video4_Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex.avi by Wesam S. Ahmed (10170053)

Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells - Fig 5 by Tadeja Kuret (5059433)

Fig 5 - by Felix Bosch (10024550)

Research data for paper: Disrupting a (far-right) mobilisation discourages bystander support by decreasing perceived organisational efficacy and legitimacy by Carina Hoerst (7143209)

Fig 5 - by Mykola Pinkevych (125551)

Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell death in TKIs-resistant and –sensitive K562 cell lines. by Octavian Bucur (470431)

“…K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells. β-Actin was used as an internal loading control. …”

Decreased echinocandin susceptibility in <i>Candida parapsilosis</i> causing candidemia and emergence of a pan-echinocandin resistant case in China by Yating Ning (11264310)